Potential for palivizumab interference with commercially available antibody-antigen based respiratory syncytial virus diagnostic assays.
Pediatr Infect Dis J
; 32(10): 1144-6, 2013 Oct.
Article
en En
| MEDLINE
| ID: mdl-23584584
Palivizumab is a monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus infection in infants. The potential for palivizumab to interfere with commercially available respiratory syncytial virus diagnostic tests was demonstrated. Negative test results in palivizumab-treated subjects should be interpreted with caution and confirmed by a nucleic acid amplification-based assay.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Virus Sincitiales Respiratorios
/
Virología
/
Inmunoensayo
/
Infecciones por Virus Sincitial Respiratorio
/
Anticuerpos Monoclonales Humanizados
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
Idioma:
En
Revista:
Pediatr Infect Dis J
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
/
PEDIATRIA
Año:
2013
Tipo del documento:
Article
Pais de publicación:
Estados Unidos